<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04960722</url>
  </required_header>
  <id_info>
    <org_study_id>BiG001A102</org_study_id>
    <nct_id>NCT04960722</nct_id>
  </id_info>
  <brief_title>OIF/β-TCP in Patients With Open Tibial Fractures in Need of Bone Grafting</brief_title>
  <official_title>A Randomized, Evaluator-blinded, Controlled Study to Evaluate the Safety and Clinical Performance of OIF/β-TCP in Patients With Open Tibial Fractures in Need of Bone Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioGend Therapeutics Co.Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioGend Therapeutics Co.Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, evaluator-blinded, controlled study for subjects with open tibial&#xD;
      fractures classified as Gustilo type II, IIIA or IIIB (see Appendix 1) who will receive bone&#xD;
      graft implantation for the potential of delayed union or non-union within 3 months of&#xD;
      fracture. Subjects will be followed for safety and clinical performance for the main study&#xD;
      period of 30 weeks and an extension follow-up period up to 52 weeks after bone graft&#xD;
      implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives:&#xD;
&#xD;
        -  Primary objectives&#xD;
&#xD;
           o To determine the overall success of effectiveness (clinical and radiographic success)&#xD;
           and safety (lack of serious product-related AEs and lack of secondary intervention) of&#xD;
           OIF/beta-TCP within 30 weeks after bone graft implantation in subjects with open tibial&#xD;
           fractures in need of bone grafting.&#xD;
&#xD;
        -  Secondary objectives&#xD;
&#xD;
             -  To determine radiographic union in different treatment groups;&#xD;
&#xD;
             -  To determine clinical union in different treatment groups;&#xD;
&#xD;
             -  To assess the safety of OIF&#xD;
&#xD;
             -  To assess the immunogenicity of OIF;&#xD;
&#xD;
             -  To determine the pharmacokinetics of OIF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic (CT scan) Union at Week 30</measure>
    <time_frame>30 weeks</time_frame>
    <description>Percentage of participants with complete fracture healing as assessed by CT scan at 30 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic (X-Ray) Union at Week 30</measure>
    <time_frame>30 weeks</time_frame>
    <description>Percentage of participants with bridging on three of four cortices assessed by X-Ray (RUST) at 30 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events at Week 30</measure>
    <time_frame>30 weeks</time_frame>
    <description>Absence of any serious product-related AEs and lack of secondary intervention after bone grafting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic-assessed bone healing</measure>
    <time_frame>52 weeks</time_frame>
    <description>Patients with complete bone healing, based on independent blinded central radiographic evaluations of the patient CT scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from bone graft implantation to CT scan radiographic fracture healing</measure>
    <time_frame>52 weeks</time_frame>
    <description>The assessment of time from bone graft implantation to first X-ray radiographic fracture healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from bone graft implantation to X-ray radiographic fracture healing</measure>
    <time_frame>52 weeks</time_frame>
    <description>The assessment of time from bone graft implantation to first X-ray radiographic fracture healing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Fracture Healing</measure>
    <time_frame>52 weeks</time_frame>
    <description>Patients is able to walk properly (Full weight bearing), no or mild pain (assessed by VAS score of 0-3) at the fracture site with full weight bearing and no fracture site tenderness on manual palpation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of OIF</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percentage of subjects who were initially seronegative to OIF at baseline and exhibit authentic positive antibodies at Day 10, Week 6, Week 24 or Week 52</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Tibia Fracture</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>autogenous bone graft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5 mg/g OIF/β-TCP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg/g OIF/β-TCP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg/g OIF/β-TCP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/g OIF/β-TCP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg/g OIF/β-TCP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/g OIF/β-TCP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OIF/β-TCP</intervention_name>
    <description>bone graft implantation</description>
    <arm_group_label>1.5 mg/g OIF/β-TCP</arm_group_label>
    <arm_group_label>2 mg/g OIF/β-TCP</arm_group_label>
    <arm_group_label>3 mg/g OIF/β-TCP</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>BiG001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Skeletally mature, male and female subjects who are &gt; 21 years old;&#xD;
&#xD;
          2. Females of non-childbearing potential or who have a negative result on pregnancy test&#xD;
             within 72 hours prior to surgery, or males;&#xD;
&#xD;
          3. Isolated open tibial fractures, which is classified as below and within 3 months of&#xD;
             initial fracture, and soft tissue stable without any sign of active infection;&#xD;
&#xD;
               1. Gustilo type II with fracture gap at least 0.5 cm in length or severe damage to&#xD;
                  the periosteum after debridement or&#xD;
&#xD;
               2. Gustilo type IIIA with fracture gap at least 0.5 cm in length or IIIB with&#xD;
                  fracture gap at least 0.5 cm in length;&#xD;
&#xD;
          4. Subjects with unilateral open tibial fractures;&#xD;
&#xD;
          5. Willing to provide signed informed consent form (ICF) prior to participation in any&#xD;
             study-related procedures and adhere to the study requirements for the length of the&#xD;
             trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded if ANY of the following exclusion criteria apply:&#xD;
&#xD;
          1. Patients with a Glasgow Coma Scale less than 15 (less than fully awake) at the time of&#xD;
             informed consent.&#xD;
&#xD;
          2. Purulent drainage from the fracture, or evidence of active osteomyelitis;&#xD;
&#xD;
          3. Compartment syndrome;&#xD;
&#xD;
          4. Inadequate neovascular status;&#xD;
&#xD;
          5. Pathological fractures; history of Paget's disease or other osteodystrophy; or history&#xD;
             of heterotopic ossification;&#xD;
&#xD;
          6. Endocrine or metabolic disorder that affects osteogenesis (e.g., hypo- or&#xD;
             hyper-thyroidism or parathyroidism, renal osteodystrophy, Ehlers-Danlos syndrome, or&#xD;
             osteogenesis imperfecta)&#xD;
&#xD;
          7. Has abnormal renal and/or hepatic functions, with Creatinine or ALT value &gt;5 times the&#xD;
             upper normal limit;&#xD;
&#xD;
          8. History of malignancy, radiotherapy, or chemotherapy for any malignancy within the&#xD;
             last 5 years. History of malignancy may include: Multiple exostoses syndrome ((also&#xD;
             known as multiple osteochondromas syndrome), an inherited condition associated with&#xD;
             bumps of cartilage on the bones, has been associated with an increased risk of&#xD;
             chondrosarcoma), any cancer prone syndrome, such as Li-Fraumeni;&#xD;
&#xD;
          9. Any autoimmune disease (e.g. Systemic Lupus Erythematosus or dermatomyositis);&#xD;
&#xD;
         10. Subjects with major psychiatric disorders, defining such disorders using standard&#xD;
             criteria such as the DSM-V&#xD;
&#xD;
         11. Subjects with Insulin-dependent Diabetes mellitus.&#xD;
&#xD;
         12. Subjects with substance and alcohol abuse;&#xD;
&#xD;
         13. Current smokers* (*CDC: An adult who has smoked 100 cigarettes in his or her lifetime&#xD;
             and who currently smokes cigarettes.);&#xD;
&#xD;
         14. Previous exposure to rhBMP-2;&#xD;
&#xD;
         15. Hypersensitivity to protein pharmaceuticals, e.g, monoclonal antibodies, gamma&#xD;
             globulins, and tricalcium phosphate;&#xD;
&#xD;
         16. History of hypersensitivity or allergy to kanamycin or aminoglycosides.&#xD;
&#xD;
         17. Treatment with any investigational therapy within 28 days of implantation surgery;&#xD;
&#xD;
         18. Treatment with prednisone for 7 days or more within previous 6 months (cumulative&#xD;
             dose&gt; 150 mg or other steroids with equivalent dose, refer to Appendix 2 in the&#xD;
             protocol); calcitonin (within previous 6 months); bisphosphonates (for 30 days or more&#xD;
             within previous 12 months); or therapeutic doses of fluoride (for 30 days within&#xD;
             previous 12 months);&#xD;
&#xD;
         19. A female that is currently pregnant or breastfeeding at time of enrollment, or have&#xD;
             plans to become pregnant with the next one year; or female subjects of childbearing&#xD;
             potential and male subjects with partners of childbearing potential that do not agree&#xD;
             to use protocol approved methods of contraception throughout the study.&#xD;
&#xD;
         20. Individuals who have undergone a bone marrow transplant for the treatment of another&#xD;
             condition;&#xD;
&#xD;
         21. Any condition that is not suitable to participate in the study based on the&#xD;
             physician's judgement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone graft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Tibial Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

